Is the next cardiovascular blockbuster on the horizon?

07/15/2013 | New York Times (tiered subscription model), The

Three drug companies are racing to bring to market a new cholesterol-lowering medication that reproduces the effects of a genetic mutation that causes extremely low LDL levels. Preliminary studies indicate the drugs are capable of reducing persistently high LDL levels to 50 or lower, leading some researchers to question whether cholesterol can be too low. Studies underway will attempt to answer some of the core public health questions, including whether the drugs can cut heart attacks and cardiovascular deaths.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC